NCT00985049 TRANSCRIBE (Transcriptomic Analysis of Left Ventricular Gene Expression)
| NCT ID | NCT00985049 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Brigham and Women's Hospital |
| Condition | Cardiovascular Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 350 participants |
| Start Date | 2009-03 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 350 participants in total. It began in 2009-03 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Hypothesis: The investigators hypothesize that genetic variants will alter gene expression in response to ischemia during cardiopulmonary bypass. To test this, the investigators will be taking small pieces of heart tissue from patients undergoing heart surgery before and after this period of ischemia. This will be compared to blood gene expression in blood cells and analyzed with the patients' genetic profile. This might allow us to assess the amount of inflammation that occurs when patients are on the heart-lung machine as well as examine the effects genes have on this critical time period.
Eligibility Criteria
Inclusion Criteria: * Aged greater than 20 years * Undergoing aortic valve surgery with or without CABG surgery * Receive and apical vent as part of the surgery Exclusion Criteria: * Will not receive an apical left ventricular vent
Contact & Investigator
Jochen D. Muehlschlegel, MD, MMSc, MBA
PRINCIPAL INVESTIGATOR
Johns Hopkins University
Frequently Asked Questions
Who can join the NCT00985049 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, studying Cardiovascular Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT00985049 currently recruiting?
Yes, NCT00985049 is actively recruiting participants. Contact the research team at dmuehlsch@jhu.edu for enrollment information.
Where is the NCT00985049 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT00985049 clinical trial?
NCT00985049 is sponsored by Brigham and Women's Hospital. The principal investigator is Jochen D. Muehlschlegel, MD, MMSc, MBA at Johns Hopkins University. The trial plans to enroll 350 participants.